LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article: Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot.

    Thümmler, Laura / Schwarzkopf, Sina / Knop, Dietmar / Ross, J Alexander / Berg, Victoria / Horn, Peter A / Lindemann, Monika

    Diagnostics (Basel, Switzerland)

    2021  Volume 11, Issue 8

    Abstract: Herd immunity is essential to control severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), especially in immunocompromised patients. Convalescent individuals should be vaccinated later due to vaccine shortage, as studies show that ... ...

    Abstract Herd immunity is essential to control severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), especially in immunocompromised patients. Convalescent individuals should be vaccinated later due to vaccine shortage, as studies show that neutralizing antibodies generated during infection are stable for at least 6 months. Cellular immunity is also detectable for months. However, there is evidence of cross-reactivity of T cells with human endemic coronaviruses (HCoVs). Here, we show that cross-reactivity-which may prevent the specific detection of SARS-CoV-2-specific T cell responses-can be avoided if cells are stimulated with the N-terminus of the spike protein in IFN-γ ELISpot. In contrast to previous studies, we examined T-cell responses against all four known HCoVs using IFN-γ ELISpot in 19 convalescent volunteers and 10 fully vaccinated volunteers. In addition, we performed Spearman analyses to detect cross-reactivity of T cells. We observed no correlation between T-cell responses against SARS-CoV-2 and human endemic coronaviruses, either in the whole cohort or in the individual groups. The use of the respective stimuli could lead to a more accurate assessment of cellular immunity in recovered individuals. This testing procedure could help to define the best time point at which convalescents should receive SARS-CoV-2 vaccination.
    Language English
    Publishing date 2021-08-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662336-5
    ISSN 2075-4418
    ISSN 2075-4418
    DOI 10.3390/diagnostics11081439
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot

    Laura Thümmler / Sina Schwarzkopf / Dietmar Knop / J. Alexander Ross / Victoria Berg / Peter A. Horn / Monika Lindemann

    Diagnostics, Vol 11, Iss 1439, p

    2021  Volume 1439

    Abstract: Herd immunity is essential to control severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), especially in immunocompromised patients. Convalescent individuals should be vaccinated later due to vaccine shortage, as studies show that ... ...

    Abstract Herd immunity is essential to control severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), especially in immunocompromised patients. Convalescent individuals should be vaccinated later due to vaccine shortage, as studies show that neutralizing antibodies generated during infection are stable for at least 6 months. Cellular immunity is also detectable for months. However, there is evidence of cross-reactivity of T cells with human endemic coronaviruses (HCoVs). Here, we show that cross-reactivity—which may prevent the specific detection of SARS-CoV-2-specific T cell responses—can be avoided if cells are stimulated with the N-terminus of the spike protein in IFN-γ ELISpot. In contrast to previous studies, we examined T-cell responses against all four known HCoVs using IFN-γ ELISpot in 19 convalescent volunteers and 10 fully vaccinated volunteers. In addition, we performed Spearman analyses to detect cross-reactivity of T cells. We observed no correlation between T-cell responses against SARS-CoV-2 and human endemic coronaviruses, either in the whole cohort or in the individual groups. The use of the respective stimuli could lead to a more accurate assessment of cellular immunity in recovered individuals. This testing procedure could help to define the best time point at which convalescents should receive SARS-CoV-2 vaccination.
    Keywords cross-reactivity ; ELISpot ; human endemic coronavirus ; Medicine (General) ; R5-920
    Subject code 616
    Language English
    Publishing date 2021-08-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients.

    Lindemann, Monika / Klisanin, Vesna / Thümmler, Laura / Fisenkci, Neslinur / Tsachakis-Mück, Nikolaos / Ditschkowski, Markus / Schwarzkopf, Sina / Klump, Hannes / Reinhardt, Hans Christian / Horn, Peter A / Koldehoff, Michael

    Vaccines

    2021  Volume 9, Issue 10

    Abstract: The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT recipients prior to and post vaccination were tested for SARS-CoV-2-specific ... ...

    Abstract The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT recipients prior to and post vaccination were tested for SARS-CoV-2-specific humoral and cellular immunity. Antibodies against spike (S) 1 were assessed by Anti-SARS-CoV-2 IgG ELISA (Euroimmun). Cellular immunity was analyzed by an
    Language English
    Publishing date 2021-09-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9101075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG

    Sina Schwarzkopf / Adalbert Krawczyk / Dietmar Knop / Hannes Klump / Andreas Heinold / Falko M. Heinemann / Laura Thümmler / Christian Temme / Marianne Breyer / Oliver Witzke / Ulf Dittmer / Veronika Lenz / Peter A. Horn / Monika Lindemann

    Emerging Infectious Diseases, Vol 27, Iss 1, Pp 122-

    2021  Volume 129

    Abstract: We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 ( ... ...

    Abstract We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 (17%) study participants had borderline or negative results to an ELISA detecting IgG against the S1 protein of SARS-CoV-2. We analyzed participants with PCR-confirmed infection who had strong antibody responses (ratio >3) as positive controls and participants without symptoms of SARS-CoV-2 infection and without household contact with infected patients as negative controls. Using interferon-γ ELISpot, we observed that 78% of PCR-positive volunteers with undetectable antibodies showed T cell immunity against SARS-CoV-2. We observed a similar frequency (80%) of T-cell immunity in convalescent donors with strong antibody responses but did not detect immunity in negative controls. We concluded that, in convalescent patients with undetectable SARS-CoV-2 IgG, immunity may be mediated through T cells.
    Keywords coronavirus disease ; SARS-CoV-2 ; severe acute respiratory syndrome coronavirus 2 ; severe acute respiratory syndrome ; SARS ; viruses ; Medicine ; R ; Infectious and parasitic diseases ; RC109-216
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Centers for Disease Control and Prevention
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients

    Monika Lindemann / Vesna Klisanin / Laura Thümmler / Neslinur Fisenkci / Nikolaos Tsachakis-Mück / Markus Ditschkowski / Sina Schwarzkopf / Hannes Klump / Hans Christian Reinhardt / Peter A. Horn / Michael Koldehoff

    Vaccines, Vol 9, Iss 1075, p

    2021  Volume 1075

    Abstract: The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT recipients prior to and post vaccination were tested for SARS-CoV-2-specific ... ...

    Abstract The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT recipients prior to and post vaccination were tested for SARS-CoV-2-specific humoral and cellular immunity. Antibodies against spike (S) 1 were assessed by Anti-SARS-CoV-2 IgG ELISA (Euroimmun). Cellular immunity was analyzed by an in house interferon-gamma ELISpot and T-SPOT. COVID (Oxford Immunotec), using altogether seven SARS-CoV-2-specific antigens. In 117 HSCT patients vaccinated twice, SARS-CoV-2 IgG antibodies were significantly higher than in HSCT controls pre vaccination ( p < 0.0001). After the second vaccination, we observed a median antibody ratio of 4.7 and 68% positive results, whereas 35 healthy controls reached a median ratio of 9.0 and 100% positivity. ELISpot responses in patients were significantly ( p < 0.001) reduced to ≤33% of the controls. After the second vaccination, female HSCT patients and female healthy controls showed significantly higher antibody responses than males (6.0 vs. 2.1 and 9.2 vs. 8.2, respectively; p < 0.05). Cellular immunity was diminished in patients irrespective of sex. In conclusion, especially male HSCT recipients showed impaired antibody responses after SARS-CoV-2 vaccination. Changing the vaccine schedule or composition could help increase vaccine responses.
    Keywords SARS-CoV-2 ; vaccination ; allogeneic hematopoietic stem cell transplantation ; antibodies ; ELISpot ; sex-dependency ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG.

    Schwarzkopf, Sina / Krawczyk, Adalbert / Knop, Dietmar / Klump, Hannes / Heinold, Andreas / Heinemann, Falko M / Thümmler, Laura / Temme, Christian / Breyer, Marianne / Witzke, Oliver / Dittmer, Ulf / Lenz, Veronika / Horn, Peter A / Lindemann, Monika

    Emerging infectious diseases

    2020  Volume 27, Issue 1

    Abstract: We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 ( ... ...

    Abstract We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 (17%) study participants had borderline or negative results to an ELISA detecting IgG against the S1 protein of SARS-CoV-2. We analyzed participants with PCR-confirmed infection who had strong antibody responses (ratio >3) as positive controls and participants without symptoms of SARS-CoV-2 infection and without household contact with infected patients as negative controls. Using interferon-γ ELISpot, we observed that 78% of PCR-positive volunteers with undetectable antibodies showed T cell immunity against SARS-CoV-2. We observed a similar frequency (80%) of T-cell immunity in convalescent donors with strong antibody responses but did not detect immunity in negative controls. We concluded that, in convalescent patients with undetectable SARS-CoV-2 IgG, immunity may be mediated through T cells.
    MeSH term(s) Adult ; Antibodies, Viral/blood ; Antibody Specificity ; Blood Donors ; COVID-19/immunology ; COVID-19/virology ; Enzyme-Linked Immunospot Assay/methods ; Female ; Humans ; Immunity, Cellular/physiology ; Immunoglobulin G/blood ; Interferon-gamma ; Male ; Middle Aged ; Polymerase Chain Reaction ; SARS-CoV-2 ; T-Lymphocytes/physiology
    Chemical Substances Antibodies, Viral ; Immunoglobulin G ; Interferon-gamma (82115-62-6)
    Keywords covid19
    Language English
    Publishing date 2020-10-15
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/2701.203772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.

    Lindemann, Monika / Krawczyk, Adalbert / Dolff, Sebastian / Konik, Margarethe / Rohn, Hana / Platte, Maximillian / Thümmler, Laura / Schwarzkopf, Sina / Schipper, Leonie / Bormann, Maren / van de Sand, Lukas / Breyer, Marianne / Klump, Hannes / Knop, Dietmar / Lenz, Veronika / Temme, Christian / Dittmer, Ulf / Horn, Peter A / Witzke, Oliver

    Journal of medical virology

    2021  Volume 93, Issue 5, Page(s) 3047–3054

    Abstract: When patients with chronic kidney disease are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) they can face two specific problems: virus-specific immune responses may be impaired and remdesivir, an antiviral drug described to ... ...

    Abstract When patients with chronic kidney disease are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) they can face two specific problems: virus-specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten recovery, is contraindicated. Antiviral treatment with convalescent plasma (CP) could be an alternative treatment option. In this case report, we present two kidney transplant recipients and two hemodialysis patients who were infected with SARS-CoV-2 and received CP. Antibodies against the receptor-binding domain in the S1 subunit of the SARS-CoV-2 spike protein were determined sequentially by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and neutralization assay and specific cellular responses by interferon-gamma ELISpot. Before treatment, in both kidney transplant recipients and one hemodialysis patient antibodies were undetectable by ELISA (ratio < 1.1), corresponding to low neutralizing antibody titers (≤1:40). ELISpot responses in the four patients were either weak or absent. After CP treatment, we observed an increase of SARS-CoV-2-specific antibodies (IgG ratio and neutralization titer) and of specific cellular responses. After intermittent clinical improvement, one kidney transplant recipient again developed typical symptoms on Day 12 after treatment and received a second cycle of CP treatment. Altogether, three patients clinically improved and could be discharged from the hospital. However, one 83-year-old multimorbid patient deceased. Our data suggest that the success of CP therapy may only be temporary in patients with chronic kidney disease; which requires close monitoring of viral load and antiviral immunity and possibly an adaptation of the treatment regimen.
    MeSH term(s) Aged ; Aged, 80 and over ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Antiviral Agents/therapeutic use ; C-Reactive Protein ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/therapy ; Enzyme-Linked Immunospot Assay/methods ; Female ; Humans ; Immunity, Cellular/immunology ; Immunity, Humoral/immunology ; Immunization, Passive/methods ; Immunoglobulin G/blood ; Kidney Transplantation ; Middle Aged ; Renal Dialysis ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Antiviral Agents ; Immunoglobulin G ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2021-02-09
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26840
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age.

    Konik, Margarethe / Lindemann, Monika / Zettler, Markus / Meller, Lara / Dolff, Sebastian / Rebmann, Vera / Horn, Peter A / Dittmer, Ulf / Krawczyk, Adalbert / Schipper, Leonie / Trilling, Mirko / Anastasiou, Olympia Evdoxia / Schwarzkopf, Sina / Thümmler, Laura / Taube, Christian / Schöbel, Christoph / Brenner, Thorsten / Skoda, Eva-Maria / Wilde, Benjamin /
    Gäckler, Anja / Witzke, Oliver / Rohn, Hana

    Journal of clinical medicine

    2021  Volume 10, Issue 19

    Abstract: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the ... ...

    Abstract The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the persistence of long-term SARS-CoV-2 immunity are not well understood. Therefore, we determined the extent of important correlates of SARS-CoV-2 specific protection in 200 unvaccinated convalescents after COVID-19. To investigate the effective memory response against the virus, SARS-CoV-2 specific T cell and humoral immunity (including virus-neutralizing antibodies) was determined over a period of one to eleven months. SARS-CoV-2 specific immune responses were present in 90% of individual patients. Notably, immunosuppressed patients did not have long-term SARS-CoV-2 specific T cell immunity. In our cohort, the severity of the initial illness influenced SARS-CoV-2 specific T cell immune responses and patients' humoral immune responses to Spike (S) protein over the long-term, whereas the patients' age influenced Membrane (M) protein-specific T cell responses. Thus, our study not only demonstrated the long-term persistence of SARS-CoV-2 specific immunity, it also determined COVID-19 severity and patient age as significant factors affecting long-term immunity.
    Language English
    Publishing date 2021-10-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10194606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Convalescent plasma treatment of critically ill intensive care COVID-19 patients.

    Lindemann, Monika / Lenz, Veronika / Knop, Dietmar / Klump, Hannes / Alt, Mira / Aufderhorst, Ulrich W / Schipper, Leonie / Schwarzkopf, Sina / Meller, Lara / Steckel, Nina / Koldehoff, Michael / Heinold, Andreas / Heinemann, Falko M / Fischer, Johannes / Hutschenreuter, Gabriele / Knabbe, Cornelius / Dolff, Sebastian / Brenner, Thorsten / Dittmer, Ulf /
    Witzke, Oliver / Herbstreit, Frank / Horn, Peter A / Krawczyk, Adalbert

    Transfusion

    2021  Volume 61, Issue 5, Page(s) 1394–1403

    Abstract: Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be life-threatening, and specific antiviral drugs are currently not available. However, first studies indicated that convalescent plasma treatment might improve ... ...

    Abstract Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be life-threatening, and specific antiviral drugs are currently not available. However, first studies indicated that convalescent plasma treatment might improve the clinical outcome of coronavirus disease 2019 (COVID-19) patients.
    Study design and methods: In the current study, we investigated the efficacy of convalescent plasma treatment in eight COVID-19 patients. All the patients were critically ill, and seven of them were SARS-CoV-2 RNA-positive when starting treatment. SARS-CoV-2-specific antibodies were determined by an enzyme-linked immunosorbent assay detecting immunoglobulin G (IgG) antibodies against the S1 protein (Euroimmun), and the neutralizing titers were determined with a cell-culture-based neutralization assay. Plasma treatment started between 4 and 23 days after the onset of symptoms. The patients were usually treated by three plasma units, each containing 200-280 ml, which was applied at day 1, 3, and 5.
    Results: Donor sera had on average lower IgG antibody ratios and neutralizing titers than the COVID-19 patients before the onset of treatment (median ratio of 5.8 and neutralizing titer of 1:320 vs. 7.5 and 1:640, respectively). Nevertheless, we observed an increase of antibody ratios in seven and of neutralizing titers in five patients after treatment; which did, however, not correlate with patient survival. Plasma treatment was effective in three patients, but five deceased despite treatment. Patients who deceased had a later treatment onset than survivors and finally died from multiple organ failure.
    Conclusion: Our data indicate that the efficacy of convalescent plasma treatment of critically ill COVID-19 patients who already had developed strong antiviral immune responses and organ complications is limited.
    MeSH term(s) Adult ; Aged ; Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Blood Donors ; COVID-19/blood ; COVID-19/therapy ; Chlorocebus aethiops ; Critical Illness ; Female ; Humans ; Immunization, Passive ; Immunoglobulin G/blood ; Male ; Middle Aged ; SARS-CoV-2/metabolism ; Vero Cells
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G
    Language English
    Publishing date 2021-04-08
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.16392
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age

    Margarethe Konik / Monika Lindemann / Markus Zettler / Lara Meller / Sebastian Dolff / Vera Rebmann / Peter A. Horn / Ulf Dittmer / Adalbert Krawczyk / Leonie Schipper / Mirko Trilling / Olympia Evdoxia Anastasiou / Sina Schwarzkopf / Laura Thümmler / Christian Taube / Christoph Schöbel / Thorsten Brenner / Eva-Maria Skoda / Benjamin Wilde /
    Anja Gäckler / Oliver Witzke / Hana Rohn

    Journal of Clinical Medicine, Vol 10, Iss 4606, p

    2021  Volume 4606

    Abstract: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the ... ...

    Abstract The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the persistence of long-term SARS-CoV-2 immunity are not well understood. Therefore, we determined the extent of important correlates of SARS-CoV-2 specific protection in 200 unvaccinated convalescents after COVID-19. To investigate the effective memory response against the virus, SARS-CoV-2 specific T cell and humoral immunity (including virus-neutralizing antibodies) was determined over a period of one to eleven months. SARS-CoV-2 specific immune responses were present in 90% of individual patients. Notably, immunosuppressed patients did not have long-term SARS-CoV-2 specific T cell immunity. In our cohort, the severity of the initial illness influenced SARS-CoV-2 specific T cell immune responses and patients’ humoral immune responses to Spike (S) protein over the long-term, whereas the patients’ age influenced Membrane (M) protein-specific T cell responses. Thus, our study not only demonstrated the long-term persistence of SARS-CoV-2 specific immunity, it also determined COVID-19 severity and patient age as significant factors affecting long-term immunity.
    Keywords COVID-19 ; SARS-CoV-2 ; immunity ; age ; T cell ; SARS-CoV-2 IgG ; Medicine ; R
    Subject code 616
    Language English
    Publishing date 2021-10-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top